By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BeiGene Co.,Ltd 

No.30 Science Park Road
Zhong-Guan-Cun Life Science Park
Changping District  Beijing    China
Phone: n/a Fax: n/a


SEARCH JOBS

BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

YEAR FOUNDED:

October 28, 2010

LEADERSHIP:

Founders: Xiaodong Wang, and John Oyler

CEO: John Oyler

CFO: Howard Liang

CMO (Medical): Eric Hedrick

JOBS:

Please click here for BeiGene job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Public

Web Site: BeiGene
Employees:
Symbol: BGNE
 



Industry
Pharmaceutical






Company News
BeiGene (BGNE) Announces Proposed Public Offering 8/10/2017 12:19:31 PM
Medidata Solutions, Inc. Expands Partnership With BeiGene (BGNE) To Use Medidata‚Äôs Patient Cloud Epro Solution 7/25/2017 10:32:55 AM
Week In Review: BeiGene (BGNE) Sets Record With $1.4 Billion Celgene (CELG) Deal 7/10/2017 12:20:05 PM
How Transformative Is This Licensing Deal For BeiGene (BGNE)? 7/7/2017 6:14:30 AM
BeiGene (BGNE) To Host Investor Conference Call On Global Strategic Collaboration With Celgene (CELG) 7/6/2017 1:00:58 PM
Biotech Bestie Celgene (CELG) Takes Stake, Inks $1 Billion+ Deal With BeiGene (BGNE) 7/6/2017 5:47:10 AM
BeiGene (BGNE) Initiates Pivotal Trial Of PD-1 Antibody BGB-A317 In China In Patients With Urothelial Cancer 7/5/2017 9:05:00 AM
BeiGene (BGNE) Presents Preliminary Phase I Data On BGB-A317 In Patients With Hepatocellular Carcinoma At The ESMO 19th World Congress On Gastrointestinal Cancer 6/29/2017 9:41:44 AM
BeiGene (BGNE) Presents Initial Phase I Data On BTK Inhibitor BGB-3111 Combined With Obinutuzumab At The 14th International Conference On Malignant Lymphoma And Announces Additional Planned Global Registrational Trials For BGB-3111 6/16/2017 8:59:55 AM
BeiGene (BGNE) Presents Updated Phase I Data On BTK Inhibitor BGB-3111 In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At The 14th International Conference On Malignant Lymphoma 6/14/2017 12:42:40 PM
12345678
//-->